Melbourne researchers have uncovered genes responsible for the way the body fights infection at the point of ‘invasion’ – whether it’s the skin, liver, lungs or the gut.
Research led by Dr Axel Kallies and Dr Klaas van Gisbergen at the Walter and Eliza Hall Institute of Medical Research, and Dr Laura Mackay from the University of Melbourne at the Peter Doherty Institute for Infection and Immunity has identified the genes Hobit and Blimp1 and found that they control a universal molecular program responsible for placing immune cells at the ‘front lines’ of the body to fight infection and cancer.
The presence of these organ-residing cells, which differ strikingly from their counterparts circulating in the blood stream, is key to local protection against viruses and bacteria.
Walter and Eliza Hall Institute’s Dr Kallies said the human body was fighting disease-causing pathogens every minute of its life. Dr Kallies said identifying how immune cells remain in the part of the body where they are needed most was critical to developing better ways to protect us from infections such as malaria or HIV.
“Discovering these ‘local heroes’ and knowing how the localised immune response is established allows us to find ways to ensure the required cells are positioned where they are needed most,” Dr Kallies said.
“This research will help us understand how immune cells adapt, survive and respond within the organs they protect. This is critical to rid the body of pathogens even before they are established and may also have implications for understanding how the spread of cancer could be prevented.”
The Doherty Institute’s Dr Laura Mackay, who is also an associate investigator with the Australian Research Council Centre of Excellence in Advanced Molecular Imaging, said the factors that control the ‘tissue-residency’ of immune cells – their ability to locally reside in different organs of the body – was previously unknown.
“These results have major implications for developing strategies to induce immune cells in tissues that protect against infectious diseases,” Dr Mackay said.
“It’s a crucial discovery for future vaccine strategies – Hobit and Blimp1 would be key to placing immune cells in the tissues, which we know are really important for protection.”
Learn more: Researchers uncover ‘local heroes’ of immune system
The Latest on: Localised immune response
[google_news title=”” keyword=”Localised immune response” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Localised immune response
- Direct measurement of the interaction between immune cells and cancer cells from a patient's biopsyon May 10, 2024 at 10:24 am
Researchers have unveiled a technology that promises to improve cancer treatment decisions based on a patient's biopsy. The pioneering biological research and development measures changes in immune ...
- RNA-LPAs Induce Immune Responses in Glioblastoma Patientson May 9, 2024 at 7:45 am
RNA lipid particle aggregates (RNA-LPAs) induced immune responses against glioblastoma in a first-in-human trial, according to a report published in Cell.1 The RNA-LPAs were designed to “enhance the ...
- What is the association between cytokines and autoimmune diseases?on May 3, 2024 at 8:01 am
Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system homeostasis. When the immune system malfunctions, irregularities in cytokine ...
- Plant science research paves the way for deeper understanding of how the plant immune system functionson April 29, 2024 at 1:40 pm
Smith, Ph.D. at the Danforth Plant Science Center and the University of Tennessee, Knoxville, are conducting pioneering work to discover how plants transmit information, important molecules, and ...
- Study rethinks immune system strategies to boost vaccine effectivenesson April 28, 2024 at 9:52 pm
A recent Cell journal review explores key immunological assumptions to enhance our understanding of vaccine design, autoimmune responses, and immune system pathology, aiming to refine intervention ...
- Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meetingon April 25, 2024 at 12:00 am
The Company is advancing a preclinical platform of conditionally-activated tri-specific antibodies that engage both T cells and NK cells to induce a strong, localized immune response within the tumor ...
- Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meetingon April 25, 2024 at 12:00 am
The Company is advancing a preclinical platform of conditionally-activated tri-specific antibodies that engage both T cells and NK cells to induce a strong, localized immune response within the ...
- Researchers Develop a New Way to Safely Boost Immune Cells to Fight Canceron April 22, 2024 at 1:56 pm
New cancer immunotherapy developed to localize cancer-killing cytokines in tumors to improve treatment effectiveness ...
- Reprogramming the immune system to attack cancer cellson April 22, 2024 at 11:45 am
They play a critical role in coordinating the immune response, attracting and activating ... addressed this challenge with their innovative localized cytokine therapy approach, providing a more ...
- Reprogramming the immune system to attack cancer cellson April 21, 2024 at 5:00 pm
They play a critical role in coordinating the immune response, attracting and activating various immune ... Researchers at Virginia Tech addressed this challenge with their innovative localized ...
via Bing News